CM
PDLI

Crestline Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Crestline Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-875,000
Closed -$1.89M – 104
2019
Q3 		$1.89M Buy
875,000
+725,000
+483% +$1.94M 0.3% 51
2019
Q2 		$471K Buy
+150,000
New +$487K 0.06% 74

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crestline Management's PDLI Position: Q4 2019 in Review

Crestline Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 875,000 shares — an estimated $1.89M sold.

Crestline Management first reported a position in PDLI in Q2 2019 and held it in 2 quarters. The position peaked at $1.89M in Q3 2019. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • Crestline Management reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Crestline Management sold 875,000 PDL BioPharma, Inc. shares in Q4 2019, an estimated $1.89M.
  • Crestline Management first reported a position in PDL BioPharma, Inc. in Q2 2019 and held it in 2 quarters.
  • Crestline Management's PDL BioPharma, Inc. position peaked at $1.89M in Q3 2019.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Crestline Management's 13F filing for Q4 2019, filed 12 Feb 2020.